(FM) Inmunología
Departamento académico
Salvador
Martín Algarra
Consultor Médico
Publicaciones en las que colabora con Salvador Martín Algarra (13)
2020
-
Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors
Science Translational Medicine, Vol. 12, Núm. 565
2018
-
Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients
Annals of Oncology, Vol. 29, Núm. 5, pp. 1312-1319
2017
-
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients
Annals of Oncology, Vol. 28, Núm. 8, pp. 1988-1995
2015
-
Enhancing T cell performance against cancer in combination treatment strategies
Cancer Drug Discovery and Development (Humana Press Inc.), pp. 245-258
-
Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγnull immunodeficient mice
Cancer Research, Vol. 75, Núm. 17, pp. 3466-3478
2014
-
Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins
Clinical Cancer Research, Vol. 20, Núm. 22, pp. 5697-5707
2012
-
CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy
Journal of Immunology, Vol. 189, Núm. 7, pp. 3299-3310
-
Immunostimulatory monoclonal antibodies for melanoma treatment
Emerging Therapeutics for Melanoma (Future Medicine Ltd.), pp. 81-91
2011
-
Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients
Journal of Immunology, Vol. 187, Núm. 11, pp. 6130-6142
-
Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo
International Journal of Cancer, Vol. 129, Núm. 2, pp. 374-386
2004
-
Acquired potential N-glycosylation sites within the tumor-specific immunoglobulin heavy chains of B-cell malignancies
Haematologica, Vol. 89, Núm. 5, pp. 541-546
-
Imatinib Inhibits Proliferation of Ewing Tumor Cells Mediated by the Stem Cell Factor/KIT Receptor Pathway, and Sensitizes Cells to Vincristine and Doxorubicin-Induced Apoptosis
Clinical Cancer Research, Vol. 10, Núm. 2, pp. 751-761